Correlation Engine 2.0
Clear Search sequence regions


  • adult (1)
  • antibodies (2)
  • bevacizumab (14)
  • bid (1)
  • breast cancer (3)
  • breast neoplasms (1)
  • cohorts (5)
  • ErbB 2 (2)
  • ERBB2 protein (1)
  • female (1)
  • free (4)
  • help (1)
  • HER2 (2)
  • humans (1)
  • metastases (2)
  • over (1)
  • paclitaxel (6)
  • patient (3)
  • phase (1)
  • protein human (1)
  • protocols (1)
  • receptor erbb- 2 (2)
  • risk disease (1)
  • risk factor (4)
  • TNBC (2)
  • treatment effect (1)
  • TURANDOT (2)
  • Sizes of these terms reflect their relevance to your search.

    The randomised phase III TURANDOT trial compared first-line bevacizumab-paclitaxel (BEV-PAC) vs bevacizumab-capecitabine (BEV-CAP) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC). The interim analysis revealed no difference in overall survival (OS; primary end point) between treatment arms; however, progression-free survival (PFS) and objective response rate were significantly superior with BEV-PAC. We sought to identify patient populations that may be most appropriately treated with one or other regimen. Patients with HER2-negative LR/mBC who had received no prior chemotherapy for advanced disease were randomised to either BEV-PAC (bevacizumab 10 mg kg(-1) days 1 and 15 plus paclitaxel 90 mg m(-2) days 1, 8 and 15 q4w) or BEV-CAP (bevacizumab 15 mg kg(-1) day 1 plus capecitabine 1000 mg m(-2) bid days 1-14 q3w). The study population was categorised into three cohorts: triple-negative breast cancer (TNBC), high-risk hormone receptor-positive (HR+) and low-risk HR+. High- and low-risk HR+ were defined, respectively, as having ⩾2 vs ⩽1 of the following four risk factors: disease-free interval ⩽24 months; visceral metastases; prior (neo)adjuvant anthracycline and/or taxane; and metastases in ⩾3 organs. The treatment effect on OS differed between cohorts. Non-significant OS trends favoured BEV-PAC in the TNBC cohort and BEV-CAP in the low-risk HR+ cohort. In all three cohorts, there was a non-significant PFS trend favouring BEV-PAC. Grade ⩾3 adverse events were consistently less common with BEV-CAP. A simple risk factor index may help in selecting bevacizumab-containing regimens, balancing outcome, safety profile and patient preference. Final OS results are expected in 2015 (ClinicalTrials.gov NCT00600340).

    Citation

    T Brodowicz, I Lang, Z Kahan, R Greil, S Beslija, S M Stemmer, B Kaufman, L Petruzelka, A Eniu, R Anghel, K Koynov, D Vrbanec, T Pienkowski, B Melichar, S Spanik, S Ahlers, D Messinger, M J Inbar, C Zielinski. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British journal of cancer. 2014 Nov 25;111(11):2051-7

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 25268370

    View Full Text